Morgan Stanley Maintains Equal-Weight on Vir Biotechnology, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michelle Gilson has maintained an Equal-Weight rating on Vir Biotechnology (NASDAQ:VIR) but lowered the price target from $27 to $15.
July 21, 2023 | 3:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Vir Biotechnology but lowered the price target from $27 to $15.
The lowering of the price target by Morgan Stanley indicates a less optimistic outlook for Vir Biotechnology, which could negatively impact investor sentiment and potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100